Carcinogenic Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is the most common gain-of-function alteration, accounting for ~30% of lung adenocarcinomas in western countries and about 10% of Asian lung adenocarcinomas (2). This evidence concerns the gene KRAS and lung adenocarcinoma.